Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development
Company continues to work toward multiple clinical readouts in 2022
Portage is accelerating studies by expanding regions and clinical sites; continued advancement of pipeline beyond iNKTs
WESTPORT, Conn., March 31, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ:PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today provided an update on its clinical development programs and announced its development goals for the remainder of 2022.
"We are pleased to report...